Alvotech reports update on initial avt02 biologics license application

Alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that alvotech received communication from the u.s. food and drug administration (fda) detailing its assessment of the march 2022 inspection of alvotech's manufacturing facility in reykjavik, iceland and alvotech's subsequent written responses to the fda.
ALVO Ratings Summary
ALVO Quant Ranking